Weill Cornell/Rockefeller/Sloan Kettering MST Program

项目摘要 三机构MD-PhD计划是威尔康奈尔医学（WCM），洛克菲勒 Sloan Kettering癌症研究所（SKI）。它的使命是培养生物医学 研究人员：一方面，对生物医学科学有深入的了解， 当代研究技能，这将使他们能够进行基础研究，以阐明基本的 与人类疾病有关的生物过程;另一方面，在人类生物学中有很好的基础， 病理生物学和临床医学，这将使他们能够将基础研究的进展转移到 了解、预防和治疗人类疾病。 这三个机构经营三个研究生院：威尔康奈尔大学医学科学研究生院 （WCGS），WCM和SKI之间的联合企业; RU的大卫洛克菲勒研究生院;以及 格斯特纳生物医学科学研究生院（GSK）。三机构MD-PhD计划是 成立于1991年，当时两个独立的MD-PhD计划，WCM-RU计划和WCM-WCGS 计划，被加入形成本计划。GSK于2009年成为该计划的一部分。 MSTP学员在WCM完成MD学位的所有要求。他们接受博士培训， 在这三个研究机构的研究实验室，并获得博士学位GSK，RU或WCGS。 接受的学员在医学院开学前的7月初到达。在最初的两年里， 计划他们完成他们的医学院课程，采取两个研究生水平的课程设计的MD-PhD 学生，并完成三个研究轮换（在三个不同的实验室），然后才安顿下来， 实验室论文当学生选择一个研究实验室，他们在研究生院注册， 与他们的论文导师有关研究生课程和论文的要求是可比的所有 MD-PhD学生，无论他们被录取的研究生院-学生可以 在任何一所研究生院交叉注册并修读课程以获得学分。在他们的研究训练结束时， 完成论文答辩后，学生们返回WMC完成临床培训。 本申请要求提供资金，以便在国际年之后继续在这三个机构进行医学博士-博士培训。 45（前身WCMC-RU计划成立于1972年; 1974年获得NIH资助）。以目前的 迭代，该计划汇集了教师在250多个独立的研究实验室。379 MD- 博士毕业于三机构MD-PhD计划及其前身;目前有137个 方案中的学生。目前的学员来自55所本科院校。平均GPA是 3.75. 94%的毕业生追求研究生临床培训; 305毕业生谁完成了 258人（85%）在医学院、研究机构或生物技术/制药公司任职。

PROJECT SUMMARY The Tri-Institutional MD-PhD Program is a joint undertaking of Weill Cornell Medicine (WCM), The Rockefeller University (RU), and the Sloan Kettering Institute for Cancer Research (SKI). Its mission is to train biomedical investigators who: on the one hand, have advanced understanding of biomedical science and a mastery of contemporary research skills, which will allow them to undertake fundamental studies to elucidate basic biological processes pertaining to human disease; and, on the other hand, are well grounded in human biology, pathobiology and clinical medicine, which will equip them to transfer advances in basic research to the understanding, prevention, and treatment of human disease. The three institutions operate three graduate schools: Weill Cornell Graduate School of Medical Sciences (WCGS), a joint undertaking between WCM and SKI; the David Rockefeller Graduate School at RU; and the Gerstner Graduate School of Biomedical Sciences (GSK) at SKI. The Tri-Institutional MD-PhD Program was formed in 1991, when two independent MD-PhD Programs, the WCM-RU Program and the WCM-WCGS Program, were joined to form the present program. GSK became part of the Program in 2009. MSTP trainees complete all requirements for the MD degree at WCM. They receive their PhD training in research laboratories in the three research institutions and receive their PhD degree from GSK, RU or WCGS. Accepted trainees arrive in early July before the start of medical school. During the first two years in the Program they complete their medical school course, take two graduate level courses designed for MD-PhD students, and complete three research rotations (in three different laboratories) before they settle into their thesis laboratory. When the students choose a research laboratory they enroll in the graduate school with which their thesis mentor is associated. The graduate course and thesis requirements are comparable for all MD-PhD students, irrespective of the graduate school in which they are matriculated—and the students can cross register and take courses for credit in any of the graduate schools. At the end of their research training, after they have defended their thesis, the students return to complete their clinical training at WMC. The present application requests funds to continue MD-PhD training at the three institutions beyond Year 45 (the predecessor WCMC-RU Program was formed in 1972; it received NIH funding in 1974). In its current iteration, the Program brings together faculty in more than 250 independent research laboratories. 379 MD- PhDs have graduated from the Tri-Institutional MD-PhD Program and its predecessors; currently there are 137 students in the Program. The current trainees come from 55 undergraduate schools. Their average GPA is 3.75. 94% of the graduates pursue post-graduate clinical training; of the 305 graduates who have completed their training, 258 (85%) have appointments in medical schools, research institutes or biotech/pharma.